Dr Jessica Mann Co-Founded AntiDote (formerly TrialReach) together with Pablo Graiver (Founder and CEO) and Dr Eithan Ephrati (Co-founder).
Antidote is a digital health company that aims to accelerate breakthroughs in potentially life-saving treatments by bridging the gap between medical research and the people who need it.
“In a world where 80% of clinical trials are delayed or closed due to lack of awareness, we use cutting-edge technology to match the right patients with the right trials. We’re helping medical researchers make progress, faster – and offering new treatment options to patients in need,” AntiDote’s website states.
Jessica started out working as a cardiologist at the National Institute for Health in Bethesda, MD after which she moved to London to complete her PhD.
She also has an impressive 15+ year track record working for the pharma industries and being involved in several successful biotech companies such as Thiakis and Speedel.
Trial Reach helps patients find clinical trails with relative ease, which gives the company access to better and more efficient data. Dr Mann continues to practice medicine while working at TrialReach.